Sector News

Matchmaking for Shire and AbbVie already? Try Allergan (of course) and Pfizer

October 16, 2014
Life sciences
Now that AbbVie has said it wants to dump Shire, we could soon have two companies back on the market–and both could prove popular as the dust settles. In fact, as Bloomberg reports, AbbVie could make a decent second choice to AstraZeneca if Pfizer so chooses.
 
And do we have to mention the fact that Allergan might be happy to step in where AbbVie is stepping out? A Shire-Allergan merger has been chatted about for some time, after all. And Allergan would dearly love to make a deal to help defend itself against Valeant Pharmaceuticals, which is determined to come in and take over.
 
Allergan reportedly has lost its chance to snap up Salix, which is now in talks with Actavis instead. With Shire back in play, it may be Allergan’s best chance to fix its Valeant problem. Provided all the legal snarls with Valeant and its buyout partner Bill Ackman could be ironed out, of course.
 
The idea of Pfizer turning away from AstraZeneca to nab AbbVie isn’t new, either. But with the Obama administration’s new tax inversion limits, the Pfizer-AZ combo looks less favorable, just as AbbVie’s Shire buyout does. So, if Pfizer CEO Ian Read doesn’t fancy a new fight in the U.K. next month–and can’t persuade AZ to come quietly–then it may want to turn toward Chicago instead.
 
Meanwhile, Shire could turn around and become a buyer again, too. If Actavis doesn’t nab Salix, then Shire might step in. Both have gastrointestinal meds, offering some synergies. Jefferies analyst David Steinberg reminds Bloomberg that Shire has been on an acquisition trail, with one smallish deal after another. It could continue to be a “serial consolidator” in the orphan drug business.
 
Of course, AbbVie may just be trying to squeeze Shire on price, so the deal might find new life. As analyst David Amsellem tells Bloomberg, “The transaction is very much alive,” Amsellem said. “It’s just a question of price, if it’s not an inversion.”
 
By Tracy Staton
 

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach